Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1993]

Should every transplant eligible NDMM patient receive a transplant?

Prof Morie Gertz - Mayo Clinic, Rochester, USA

Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA...

Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City...

$Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy ( Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, USA )$

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma...

Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients ( Dr Jakub Radocha - Charles University, Hradec Kralove, Czech Republic )

Idecabtagene vicleucel for relapsed and refractory multiple myeloma

Prof Larry Anderson - UT Southwestern Medical Center, Dallas, USA

$Idecabtagene vicleucel for relapsed and refractory multiple myeloma ( Prof Larry Anderson - UT Southwestern Medical Center, Dallas, USA )$

Myelodysplastic syndromes (MDS)

Dr Fernando Vargas - Memorial Healthcare System, FL, USA

Myelodysplastic syndromes (MDS) ( Dr Fernando Vargas - Memorial Healthcare System, FL, USA )

Updates in Hodgkin’s and non-Hodgkin lymphomas

Dr Jose Sandoval-Sus - Moffitt Cancer Center, Tampa, USA

Updates in Hodgkin’s and non-Hodgkin lymphomas ( Dr Jose Sandoval-Sus - Moffitt Cancer Center, Tampa, USA )

OncoAlert and ecancer weekly round up for July 19 - July 25, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for July 19 - July 25, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer weekly round up for July 1- July 10, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for July 1- July 10, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R...

Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell acute lymphoblastic leukaemia ( Dr Bijal Shah - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and...

Prof Thierry Facon - Chu De Lille, Lille, France

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed MM ( Prof Thierry Facon - Chu De Lille, Lille, France )

The clinical value of maintenance in multiple myeloma

Prof Wee Joo Chng - National University of Singapore, Singapore

The clinical value of maintenance in multiple myeloma ( Prof Wee Joo Chng - National University of Singapore, Singapore )

More from ecancer